Researchers found that SARS-CoV-2 clinical resistance to Paxlovid in the EPIC-HR study was infrequent, occurring in 6 of 530 treated participants (1.1%).
Study shows resistance to Paxlovid is uncommon
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- US flu season shows signs of peak
- Hospitalized COVID patients at higher risk for organ-related death, readmission for 2.5 years, data suggest
- Liberals’, conservatives’ trust in US government’s use of digital health data diverged during COVID
- Report: COVID survivors nearly twice as likely to have ongoing symptoms as those with flu